Abstract
The Standards, Options and Recommendations on the use of erythropoietin in cancer patients are recalled. The recent literature is analysed and allows some further comments to the SOR. Medico-economic aspects, new schedules of administration, extra-hematologic virtues of erythropoietin and its impact on cancer outcomes are debated.
MeSH terms
-
Adult
-
Anemia / chemically induced
-
Anemia / drug therapy*
-
Brain / drug effects
-
Child
-
Cognition Disorders / chemically induced
-
Cognition Disorders / prevention & control
-
Darbepoetin alfa
-
Epoetin Alfa
-
Erythropoietin / adverse effects
-
Erythropoietin / analogs & derivatives
-
Erythropoietin / therapeutic use*
-
Heart / drug effects
-
Hematinics / adverse effects
-
Hematinics / therapeutic use*
-
Humans
-
Medical Oncology / standards
-
Practice Guidelines as Topic*
-
Recombinant Proteins
Substances
-
Hematinics
-
Recombinant Proteins
-
epoetin beta
-
Erythropoietin
-
Darbepoetin alfa
-
Epoetin Alfa